Jolanda Howe - 18 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
18 Mar 2025
Net transactions value
-$107,343
Form type
4
Filing time
19 Mar 2025, 17:40:09 UTC
Previous filing
18 Mar 2025
Next filing
03 Jul 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Sale $107,343 -2,415 -50% $44.45 2,426 18 Mar 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
F2 The weighted average sale price for the transaction reported was $44.448421, and the range of prices were between $44.21 and $44.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.